Product Description
Acupuncture in the treatment of acute toxicity during and after head and neck cancer radiotherapy; In this interim analysis, acupuncture leads to lower pain andfaster disappearance of skin and mucosal toxicity after (chemo)radiotherapy of head and neck cancer. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/32597419/)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Australia
Approved Indications: None
Known Adverse Events: None
Company: Zhejiang University
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Taiwan, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Breast Cancer|Breast Diseases|Dyslipidemia|Obesity|Peripheral Nervous System Diseases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05458284 |
NCT05458284 | P2 |
Active, not recruiting |
Peripheral Nervous System Diseases|Breast Diseases|Breast Cancer |
2026-07-01 |
2025-08-29 |
Primary Completion Date|Primary Endpoints |
|
NCT06703788 |
MOHW113-CMAP-M-113-000003-B | P2 |
Recruiting |
Dyslipidemia|Obesity |
2025-06-01 |
2024-11-27 |
Primary Endpoints|Treatments |